Towa Pharmaceutical Co., Ltd.
4553.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥260 | ¥228 | ¥209 | ¥166 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Cost of Goods Sold | ¥165 | ¥147 | ¥136 | ¥95 |
| Gross Profit | ¥95 | ¥81 | ¥73 | ¥70 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| R&D Expenses | ¥16 | ¥13 | ¥15 | ¥11 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥71 | ¥50 | ¥52 | ¥40 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | -¥16 | ¥0 | ¥0 | -¥1 |
| Operating Expenses | ¥71 | ¥64 | ¥67 | ¥51 |
| Operating Income | ¥23 | ¥18 | ¥6 | ¥19 |
| % Margin | 9% | 7.7% | 2.6% | 11.6% |
| Other Income/Exp. Net | ¥3 | ¥7 | -¥1 | ¥3 |
| Pre-Tax Income | ¥26 | ¥24 | ¥5 | ¥22 |
| Tax Expense | ¥7 | ¥8 | ¥2 | ¥6 |
| Net Income | ¥19 | ¥16 | ¥2 | ¥16 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS | 385.7 | 328.58 | 44.72 | 323.35 |
| % Growth | 17.4% | 634.7% | -86.2% | – |
| EPS Diluted | 385.7 | 328.58 | 44.72 | 316.19 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥2 | ¥1 | ¥1 | ¥0 |
| Depreciation & Amortization | ¥20 | ¥18 | ¥19 | ¥11 |
| EBITDA | ¥48 | ¥36 | ¥25 | ¥29 |
| % Margin | 18.5% | 15.6% | 12% | 17.8% |